Shelton, CT – PerkinElmer, a global leader in analytical solutions and specialized services for the life sciences, applied, and food markets, today announced the completion of its acquisition of SimoTech, a trusted provider of manufacturing automation and GMP IT solutions to the life sciences industry, following the company’s announcement of the signed transaction on August 11, 2026.

Founded in 2011 and headquartered in Cork, Ireland, SimoTech has evolved into one of the leading automation and manufacturing technology services providers in the biopharmaceutical market, supporting half of the world’s top 20 pharmaceutical and biotechnology companies. SimoTech collaborates with life sciences organizations to develop, implement, and manage automation and digital manufacturing solutions that accelerate project execution, enhance operational performance, and increase manufacturing flexibility, while ensuring regulatory compliance.

This acquisition marks an expansion of PerkinElmer’s solutions for the life sciences industry, which include OneSource integrated laboratory and digital solutions as well as Project Farma’s manufacturing and engineering solutions platform. It further reinforces PerkinElmer’s standing as a premier provider of life sciences services that help accelerate research, development and the manufacturing of life-saving treatments.

“By combining SimoTech’s expertise in manufacturing automation and digital systems with the capabilities of OneSource and Project Farma, this acquisition creates a significant opportunity to build a differentiated, scaled platform for pharmaceutical services,” said Michael Stubblefield, Chief Executive Officer, PerkinElmer. “We are excited to welcome SimoTech’s exceptional team to the PerkinElmer family.”

“The combination of OneSource, Project Farma and SimoTech creates a unique opportunity to strengthen our partnerships with leading innovators and reduce the time to market for life-changing therapies. SimoTech’s expertise in automation and IT systems is a natural complement to our capabilities, enabling us to support customers across the full drug development and manufacturing lifecycle. Together, we bring highly complementary capabilities that position us to deliver greater value to our customers, unlock new opportunities for growth, and realize the full potential of a differentiated, scaled pharmaceutical services platform,” said Anshul Mangal, President of PerkinElmer’s Pharma Specialty Services business.

Media Contact